Drugs / Mevidalen
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT04258826 | Jan 2021 → Jan 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03942029 | Jun → Dec 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03616795 | Aug → Nov 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02603861 | Nov 2015 → Mar 2016 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02562768 | Sep 2015 → Mar 2017 | Parkinson disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02365571 | Feb → May 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT06538116 | Aug 2024 → May 2026 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT03305809 | Nov 2017 → Jul 2020 | Lewy body dementia | Eli Lilly and Company | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mevidalen | “Phase 1 single-ascending-dose (SAD; NCT03616795) and multiple-ascending-dose (MAD; NCT02562768) studies with the D1PAM mevidalen (LY3154207) were conducted with healthy subjects.” PMID 33029934 ↗ Oct 20203“mevidalen (LY3154207) were conducted with healthy subjects.” PMID 33029934 ↗ Oct 2020 “Mevidalen (LY3154207) is a positive allosteric modulator” PMID 34664427 ↗ Oct 2021 |
| Known as | LY3154207 | “mevidalen (LY3154207) were conducted with healthy subjects.” PMID 33029934 ↗ Oct 2020 |
| Action | Activate | “Mevidalen (LY3154207) is a positive allosteric modulator of the dopamine D1 receptor” PMID 34664427 ↗ Oct 20211“Dopamine D1 receptor positive allosteric modulator” CHEMBL3421729 ↗ |
| Modality | Small molecule | — CHEMBL3421729 ↗ |
| Route | Oral | “Administered orally” NCT02365571 ↗ |
| Target | DRD1 | “Dopamine D1 receptor positive allosteric modulator” CHEMBL3421729 ↗ |